Endpoints News 23. März 2026 Novartis to invest $480M in China following AstraZeneca and Lilly pledges
Endpoints News 20. März 2026 Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Endpoints News 26. Feb. 2026 Novartis to build another radioligand factory; Germany steps up probe into Gerresheimer
Endpoints News 20. Feb. 2026 Novartis to divest India unit to private equity-led consortium for $159M
Endpoints News 18. Feb. 2026 Novartis signs macrocyclic deal with Unnatural Products for $100M upfront
Endpoints News 18. Feb. 2026 Lilly's Zepbound, Taltz combo data in psoriasis and weight loss; Novartis bolsters Rhapsido results
Endpoints News 13. Jan. 2026 Novartis licenses radiopharma asset from Chinese biotech for $50M upfront
Endpoints News 12. Jan. 2026 Novartis, SciNeuro to work together on preclinical amyloid-targeting drug for Alzheimer’s
Endpoints News 8. Dez. 2025 #ASH25: Will a biotech’s pivot away from obesity let it compete with Novartis in leukemia?